Mathias Oelke

List of Publications by Year
in descending order

44 papers	1,722 citations	279798 23 h-index	289244 40 g-index
45 all docs	45 docs citations	45 times ranked	2329 citing authors

#	Article	IF	Citations
1	Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Igâ€“coated artificial antigen-presenting cells. Nature Medicine, 2003, 9, 619-625.	30.7	291
2	Adoptive T Cell Immunotherapy For Cancer. Rambam Maimonides Medical Journal, 2015, 6, e0004.	1.0	187
3	Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. ACS Nano, 2015, 9, 6861-6871.	14.6	119
4	Nanoscale artificial antigen presenting cells for T cell immunotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 119-129.	3.3	109
5	Molecular Identification of GD3 as a Suppressor of the Innate Immune Response in Ovarian Cancer. Cancer Research, 2012, 72, 3744-3752.	0.9	78
6	Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. International Journal of Cancer, 2001, 91, 749-756.	5.1	73
7	Telomere Length as an Indicator of the Robustness of B- and T-Cell Response to Influenza in Older Adults. Journal of Infectious Diseases, 2015, 212, 1261-1269.	4.0	69
8	<i>In vivo</i> Administration of Artificial Antigen-Presenting Cells Activates Low-Avidity T Cells for Treatment of Cancer. Cancer Research, 2009, 69, 9376-9384.	0.9	61
9	Sprouty-2 regulates HIV-specific T cell polyfunctionality. Journal of Clinical Investigation, 2014, 124, 198-208.	8.2	49
10	Dietary fatty acids modulate antigen presentation to hepatic NKT cells in nonalcoholic fatty liver disease. Journal of Lipid Research, 2010, 51, 1696-1703.	4.2	45
11	In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunology, Immunotherapy, 2009, 58, 209-220.	4.2	43
12	Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells. Blood, 2008, 111, 3546-3552.	1.4	42
13	Artificial antigen-presenting cells: artificial solutions for real diseases. Trends in Molecular Medicine, 2005, 11, 412-420.	6.7	38
14	T-Cell Memory Responses Elicited by Yellow Fever Vaccine are Targeted to Overlapping Epitopes Containing Multiple HLA-I and -II Binding Motifs. PLoS Neglected Tropical Diseases, 2013, 7, e1938.	3.0	38
15	Selective Effects of mTOR Inhibitor Sirolimus on NaÃ¯ve and CMV-Specific T Cells Extending Its Applicable Range Beyond Immunosuppression. Frontiers in Immunology, 2018, 9, 2953.	4.8	33
16	Differential Innate Immune Cell Activation and Proinflammatory Response in Anaplasma phagocytophilum Infection. Infection and Immunity, 2007, 75, 3124-3130.	2.2	30
17	Overview of a HLA-Ig based â€œLego-like systemâ€•for T cell monitoring, modulation and expansion. Immunologic Research, 2010, 47, 248-256.	2.9	29
18	VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells. Clinical Cancer Research, 2016, 22, 4249-4258.	7.0	28

#	Article	IF	Citations
19	Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells. Journal of Immunological Methods, 2009, 346, 38-44.	1.4	27
20	Cord bloodâ€"derived T cells allow the generation of a more naÃ¯ve tumorâ€reactive cytotoxic Tâ€cell phenotype. Transfusion, 2018, 58, 88-99.	1.6	27
21	Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells. Oncotarget, 2016, 7, 68503-68512.	1.8	26
22	Killer artificial antigen-presenting cells: the synthetic embodiment of a â€˜guided missileâ€™. Immunotherapy, 2010, 2, 539-550.	2.0	24
23	Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells. Clinical Cancer Research, 2020, 26, 3384-3396.	7.0	24
24	HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement. Clinical Immunology, 2004, 110, 243-251.	3.2	23
25	CD47 Enhances<i>In Vivo</i>Functionality of Artificial Antigen-Presenting Cells. Clinical Cancer Research, 2015, 21, 2075-2083.	7.0	23
26	Dynamic regulation of functionally distinct virus-specific T cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3669-3674.	7.1	22
27	Ascites Specific Inhibition of CD1d-Mediated Activation of Natural Killer T Cells. Clinical Cancer Research, 2008, 14, 7652-7658.	7.0	21
28	IL-2 Upregulates CD86 Expression on Human CD4+ and CD8+ T Cells. Journal of Immunology, 2012, 188, 1620-1629.	0.8	19
29	Decline of influenza-specific CD8+ T cell repertoire in healthy geriatric donors. Immunity and Ageing, 2011, 8, 6.	4.2	18
30	Evaluation of Topoisomerase-1-Specific CD8+ T-Cell Response in Systemic Sclerosis. Annals of the New York Academy of Sciences, 2005, 1062, 137-145.	3.8	15
31	Technological advances in adoptive immunotherapy. Drugs of Today, 2005, 41, 13.	2.4	13
32	Identification of beta-subunit of bacterial RNA-polymerase--a non-species-specific bacterial protein--as target of antibodies in primary biliary cirrhosis. Digestive Diseases and Sciences, 2003, 48, 561-569.	2.3	12
33	Expansion of human cytomegalovirus-specific TÂlymphocytes from unfractionated peripheral blood mononuclear cells with artificial antigen-presenting cells. Transfusion, 2007, 47, 2143-2152.	1.6	12
34	HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL. Journal of Visualized Experiments, 2011, , .	0.3	12
35	Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies. Journal of Translational Medicine, 2011, 9, 175.	4.4	12
36	Development of an Artificial-Antigen-Presenting-Cell-Based Assay for the Detection of Low-Frequency Virus-Specific CD8 + T Cells in Whole Blood, with Application for Measles Virus. Vaccine Journal, 2009, 16, 1066-1073.	3.1	11

#	Article	IF	Citations
37	Soluble Recombinant CMVpp65 Spanning Multiple HLA Alleles for Reconstitution of Antiviral CD4+ and CD8+ T-Cell Responses After Allogeneic Stem Cell Transplantation. Journal of Immunotherapy, 2010, 33, 60-72.	2.4	9
38	Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells. Journal of Visualized Experiments, 2014, , e51859.	0.3	5
39	Soluble MHC class I complexes for targeted immunotherapy. Life Sciences, 2018, 209, 255-258.	4.3	4
40	Quality and quantity: new strategies to improve immunotherapy of cancer. Trends in Molecular Medicine, 2004, 10, 205-208.	6.7	1
41	Evaluation of Different Co-Stimulatory Signals in the Priming and Expansion of HLA-B*0702/CMV_pp65 Restricted CTLs after Stimulation with aAPC. Blood, 2008, 112, 4902-4902.	1.4	0
42	Enrichment and Expansion of Mart-1, NY-ESO and WT1 Specifc CD8+ T Cells Using Nano-Particle Artificial Antigen Presenting Cells (Nano-aAPCs). Blood, 2014, 124, 2443-2443.	1.4	0
43	Redirection of Antigen-Specific T Cells to Tumor Cells Using Nanoparticle-Based Antigen-Specific Redirectors (ATRs). Blood, 2014, 124, 2753-2753.	1.4	0
44	Immunotherapy with enhanced self immune cells. Discovery Medicine, 2004, 4, 203-7.	0.5	0